Comparison of Survival in Patients with Isolated Peritoneal Carcinomatosis from Colorectal Cancer Treated with Cytoreduction and Melphalan or Mitomycin-C as Hyperthermic Intraperitoneal Chemotherapy Agent.
Conclusions: CRS/HIPEC with MMC had longer median PFS in PC from CRC. PCI≥20 was the only independent predictive factor for survival. Until longer follow-up is available, we recommend using MMC in CRS/HIPEC for PC from CRC. Further prospective randomized studies are necessary.
PMID: 30643644 [PubMed - in process]
Source: International Journal of Surgical Oncology - Category: Surgery Tags: Int J Surg Oncol Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Colorectal Cancer | Databases & Libraries | Perfusion | Peritoneal Cancer | Study | Surgery